<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Innate Pharma — News on 6ix</title>
<link>https://6ix.com/company/innate-pharma</link>
<description>Latest news and press releases for Innate Pharma on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/innate-pharma" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836182178dffbe2df13dd55.webp</url>
<title>Innate Pharma</title>
<link>https://6ix.com/company/innate-pharma</link>
</image>
<item>
<title>Innate Pharma to Participate in the D. Boral Capital Global Conference</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-d-boral-capital-global-conference</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-d-boral-capital-global-conference</guid>
<pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
<description>MARSEILLE, France, April 23, 2026--Innate Pharma to participate in the D. Boral Capital Global Conference</description>
</item>
<item>
<title>Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-present-matisse-phase-2-interim-results-of-iph5201-in-clinical-trials-plenary-session-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-present-matisse-phase-2-interim-results-of-iph5201-in-clinical-trials-plenary-session-at-aacr-2026</guid>
<pubDate>Fri, 17 Apr 2026 19:00:00 GMT</pubDate>
<description>MARSEILLE, France, April 17, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22,</description>
</item>
<item>
<title>Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-may-21-2026</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-hold-its-annual-general-meeting-of-shareholders-on-may-21-2026</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual</description>
</item>
<item>
<title>Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-present-at-the-aacr-2026-oncology-industry-partnering-event</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-present-at-the-aacr-2026-oncology-industry-partnering-event</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that</description>
</item>
<item>
<title>Innate Pharma to Participate in the Kempen Life Sciences Conference</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-kempen-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-kempen-life-sciences-conference</guid>
<pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage</description>
</item>
<item>
<title>Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-27</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-27</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the</description>
</item>
<item>
<title>Innate Pharma Reports Full Year 2025 Financial Results and Business Update</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-reports-full-year-2025-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-reports-full-year-2025-financial-results-and-business-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing</description>
</item>
<item>
<title>Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-announces-conference-call-and-webcast-for-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-announces-conference-call-and-webcast-for-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, March 19, 2026--Innate Pharma announces conference call and webcast for full year 2025 financial results</description>
</item>
<item>
<title>Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026</title>
<link>https://6ix.com/company/innate-pharma/news/number-of-shares-and-voting-rights-of-innate-pharma-as-of-february-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/number-of-shares-and-voting-rights-of-innate-pharma-as-of-february-19-2026</guid>
<pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, February 19, 2026--Number of shares and voting rights of Innate Pharma as of February 19, 2026</description>
</item>
<item>
<title>Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-to-participate-in-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Wed, 18 Feb 2026 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, February 18, 2026--Innate pharma to participate in the Leerink Partners Global Healthcare Conference</description>
</item>
<item>
<title>Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025</title>
<link>https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000841</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000841</guid>
<pubDate>Wed, 07 Jan 2026 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, January 07, 2026--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of December 31, 2025:</description>
</item>
<item>
<title>Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025</title>
<link>https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000455</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000455</guid>
<pubDate>Mon, 22 Dec 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, December 22, 2025--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as of December 18, 2025:</description>
</item>
<item>
<title>Innate Pharma Releases Its 2026 Financial Calendar</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-releases-2026-financial-060000097</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-releases-2026-financial-060000097</guid>
<pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, December 11, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2026 financial calendar:</description>
</item>
<item>
<title>Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025</title>
<link>https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000741</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/number-shares-voting-rights-innate-060000741</guid>
<pubDate>Fri, 28 Nov 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, November 28, 2025--Number of shares and voting rights of Innate Pharma as of November 27, 2025</description>
</item>
<item>
<title>Innate Pharma to Present at Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-present-jefferies-global-060000891</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-present-jefferies-global-060000891</guid>
<pubDate>Mon, 17 Nov 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, November 17, 2025--Innate Pharma to present at Jefferies Global Healthcare Conference</description>
</item>
<item>
<title>Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-reports-third-quarter-060000459</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-reports-third-quarter-060000459</guid>
<pubDate>Thu, 13 Nov 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, November 13, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine months of 2025.</description>
</item>
<item>
<title>Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-announces-fda-clearance-060000814</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-announces-fda-clearance-060000814</guid>
<pubDate>Mon, 10 Nov 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, November 10, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.</description>
</item>
<item>
<title>Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-announces-conference-call-060000445</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-announces-conference-call-060000445</guid>
<pubDate>Wed, 05 Nov 2025 06:00:00 GMT</pubDate>
<description>MARSEILLE, France, November 05, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025.</description>
</item>
<item>
<title>Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-host-analyst-investor-050000688</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-host-analyst-investor-050000688</guid>
<pubDate>Tue, 14 Oct 2025 05:00:00 GMT</pubDate>
<description>MARSEILLE, France, October 14, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it will host an analyst and investor event focused on lacutamab, an asset with path to potential Accelerated Approval based on existing long-term follow-up data of the Phase 2 TELLOMAK study, providing both clinical perspectives and market outlook. The event will be held in person and virtually on Tuesday, October 28, 2025, from 8:00 a.m. to</description>
</item>
<item>
<title>Innate Pharma Reports First Half 2025 Business Update and Financial Results</title>
<link>https://6ix.com/company/innate-pharma/news/innate-pharma-reports-first-half-050000210</link>
<guid isPermaLink="true">https://6ix.com/company/innate-pharma/news/innate-pharma-reports-first-half-050000210</guid>
<pubDate>Wed, 17 Sep 2025 05:00:00 GMT</pubDate>
<description>MARSEILLE, France, September 17, 2025--Innate Pharma Reports First Half 2025 Business Update And Financial Results</description>
</item>
</channel>
</rss>